Screening Colonoscopy in Addison's Disease: Minor or Moderate Stress-Dose Coverage
A single patient with well-controlled Addison's disease facing a routine procedure whose real stress category depends on what happens mid-case, not on how it was referred.
Desmond O., a 58-year-old man, has spent most weekends for twenty years in his garage building furniture, and jokes that his hands have gotten steadier with age even as everything else has not. He was diagnosed with autoimmune Addison's disease fifteen years ago and has been stable since on hydrocortisone 15-10-5 mg and fludrocortisone 0.1 mg, with a laminated sick-day card he says he has never actually had to use. He is due for a screening colonoscopy next week, and a finding on his prior exam five years ago — two small tubular adenomas removed at that time — makes a polypectomy this time around likely rather than hypothetical.
That single detail is the whole disagreement. Bornstein et al.'s 2016 Endocrine Society guideline, and the UK Society for Endocrinology's emergency stress-dosing guidance built on the same framework, both categorize straightforward diagnostic endoscopy as minor stress — doubling the oral dose the day of the procedure and resuming normal dosing the next day — while categorizing endoscopy WITH intervention, including polypectomy, as moderate stress warranting parenteral coverage. Desmond's procedure is scheduled as a screening colonoscopy, which reads as minor on the referral, but its most likely actual outcome is the moderate-stress category, decided partway through a sedated procedure with no easy mid-case way to add IV access or call for medication if nobody anticipated needing it. His referral itself notes "prior tubular adenomas, recommend removal if recurrent" in the same line as the appointment type — the moderate-stress trigger and the minor-stress label are sitting in the same sentence of his own chart. A 2024 prospective study of stress dosing and adrenal crisis by Tschaidse et al. found that a meaningful share of real crises trace back to exactly this kind of category misjudgment — a stressor initially read as minor that escalated without matching coverage — rather than to patients skipping a protocol they knew they needed. Desmond himself has no strong opinion either way; he says he trusts whichever plan the team agrees on, and would rather not be the one deciding mid-procedure.
Pre-procedure planning, one week out
He's been stable for fifteen years and has never once needed sick-day dosing outside a real illness. A screening colonoscopy is a minor-stress procedure by every framework I know — double his oral dose the morning of, resume normally the next day. I'd rather not put in an IV line and expose him to parenteral hydrocortisone's own hyperglycemia risk for a procedure that's likely to stay purely diagnostic.
I don't disagree that most screening colonoscopies are minor stress — but Bornstein's own 2016 Endocrine Society guideline defines the category by whether intervention occurs, not by the referral's label, and he had two adenomas removed five years ago. Likely intervention is exactly the moderate-stress definition. Tschaidse et al.'s 2024 prospective study found that real crises more often trace to a stressor misjudged as minor than to a patient skipping a known protocol — that's the failure mode I'm trying to avoid here, not a hypothetical one.
The overtreatment concern is real, but a single 50 mg IV dose before a procedure he's already sedated for isn't the same cost as the ongoing supraphysiologic dosing that actually drives Cushingoid harm — this is one dose, not a regimen change.
I don't need either of you to win this in advance. Give him the oral double-dose the morning of as the floor — that's harmless either way — and I'll have IV hydrocortisone drawn up with the sedation nurse so it's given the moment a polypectomy actually starts, not preemptively for a procedure that might stay diagnostic. That way we're not committing to moderate-stress coverage on a maybe, and we're not caught short if it becomes one.
Agreed: oral double-dose the morning of the procedure as a floor, with IV hydrocortisone 50 mg drawn up and given only if a polypectomy or bleeding actually occurs during the case.
Not agreed: whether this bedside-contingent approach should become his standing plan for future surveillance colonoscopies, or whether — given that he is now a documented adenoma-recurrence patient — every future procedure should simply be pre-classified as moderate stress going forward. The endocrinologist leans toward locking in moderate-stress coverage for next time; the primary care physician would rather reassess year to year rather than escalate his standing protocol on one procedure's outcome.